⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
8,708
Total Claims
$4.2M
Drug Cost
742
Beneficiaries
$5,681
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+44%
Cost per patient vs peers
$5,681 vs $3,933 avg
+2%
Brand preference vs peers
52.0% vs 51.2% avg
Brand vs Generic
48% generic
Brand: 4,182 claims · $4.0M
Generic: 3,862 claims · $85K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 665 | $793K |
| Dulaglutide | 299 | $368K |
| Insulin Aspart | 232 | $349K |
| Insulin Glargine,hum.Rec.Anlog | 365 | $304K |
| Insulin Lispro | 216 | $246K |
| Empagliflozin | 176 | $185K |
| Insulin Degludec | 99 | $159K |
| Tirzepatide | 137 | $154K |
| Insulin Lispro | 103 | $143K |
| Sitagliptin Phosphate | 146 | $136K |
| Insulin Aspart | 83 | $112K |
| Dapagliflozin Propanediol | 107 | $102K |
| Insulin Pump Cart,automated,bt | 105 | $87K |
| Insulin Lispro | 47 | $85K |
| Insulin Glargine,hum.Rec.Anlog | 82 | $73K |
Prescribing Profile
Patient Profile
73
Avg Age
58%
Female
1.74
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About